GURUFOCUS.COM » STOCK LIST » USA » NAS » Enanta Pharmaceuticals Inc (NAS:ENTA) » Definitions » GF Value Rank
Switch to:

Enanta Pharmaceuticals GF Value Rank

: 1 (As of Today)
View and export this data going back to 2013. Start your Free Trial

Enanta Pharmaceuticals has the GF Value Rank of 1.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Competitive Comparison

For the Biotechnology subindustry, Enanta Pharmaceuticals's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Enanta Pharmaceuticals GF Value Rank Distribution

For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Enanta Pharmaceuticals's GF Value Rank falls into.



Enanta Pharmaceuticals GF Value Rank Related Terms

Thank you for viewing the detailed overview of Enanta Pharmaceuticals's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Enanta Pharmaceuticals Business Description

Enanta Pharmaceuticals logo
Traded in Other Exchanges
Address
500 Arsenal Street, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Executives
Russell Lesley director 41 MOORES RD. FRAZER PA 19355
Peterson Kristine director AMARIN CORPORATION MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE MYSTIC CT 06355
Foletta Mark G director AMYLIN PHARMACEUTICALS INC 9360 TOWNE CENTRE DR SAN DIEGO CA 92121
Hata Yujiro S director C/O XENCOR, INC. 111 WEST LEMON AVENUE MONROVIA CA 91016
Luu Brendan officer: Sr. VP, Business Dev. C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472
Kieffer Tara Lynn officer: Sr. VP, New Product Dev. C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472
Adda Nathalie officer: Sr. VP & Chief Medical Officer C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472
Gardiner Nathaniel S. director C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472
Golumbeski George director C/O CELGENE CORP. 86 MORRIS AVENUE SUMMIT NJ 07901
Ocain Tim officer: Senior Vice President C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472
Carter Bruce L A director C/O ZYMOGENETICS, INC. 1201 EASTLAKE AVENUE SEATTLE WA 98102
Saints Capital Granite, L.p. 10 percent owner 475 SANSOME STREET SUITE 1850 SAN FRANCISCO CA 94111
Saints Capital Granite, Llc 10 percent owner 475 SANSOME STREET, SUITE 1850 SAN FRANCISCO CA 94111
Obp (bermuda) Iii - Holdings Llc 10 percent owner 475 SANSOME STREET, SUITE 1850 SAN FRANCISCO CA 94111
Mrna - Holdings Llc 10 percent owner 475 SANSOME STREET, SUITE 1850 SAN FRANCISCO CA 94111

Enanta Pharmaceuticals Headlines

From GuruFocus

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)